335 related articles for article (PubMed ID: 28077399)
1. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
[TBL] [Abstract][Full Text] [Related]
2. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Arch Pathol Lab Med; 2016 Dec; 140(12):1345-1363. PubMed ID: 27841667
[TBL] [Abstract][Full Text] [Related]
3. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Bartley AN; Washington MK; Colasacco C; Ventura CB; Ismaila N; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
J Clin Oncol; 2017 Feb; 35(4):446-464. PubMed ID: 28129524
[TBL] [Abstract][Full Text] [Related]
4. First comprehensive guideline released for the assessment of HER2 in patients with GEA.
Washington MK
MLO Med Lab Obs; 2017 Mar; 49(3):30-1. PubMed ID: 29924569
[No Abstract] [Full Text] [Related]
5. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
[TBL] [Abstract][Full Text] [Related]
6. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
8. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
Zhao D; Klempner SJ; Chao J
J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
[TBL] [Abstract][Full Text] [Related]
9.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
10. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Tabernero J; Shen L; Elimova E; Ku G; Liu T; Shitara K; Lin X; Boyken L; Li H; Grim J; Ajani J
Future Oncol; 2022 Sep; 18(29):3255-3266. PubMed ID: 36000541
[TBL] [Abstract][Full Text] [Related]
11. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ismaila N; Ajani JA
J Oncol Pract; 2017 Jan; 13(1):53-57. PubMed ID: 27907277
[No Abstract] [Full Text] [Related]
12.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
13. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.
Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M
Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032
[TBL] [Abstract][Full Text] [Related]
14. HER2 testing in gastric cancer: a practical approach.
Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
[TBL] [Abstract][Full Text] [Related]
15. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
J Clin Oncol; 2013 Nov; 31(31):3997-4013. PubMed ID: 24101045
[TBL] [Abstract][Full Text] [Related]
17. Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice.
Lau-Min KS; Li Y; Eads JR; Wang X; Meropol NJ; Mamtani R; Getz KD
Cancer; 2021 Jul; 127(14):2562-2570. PubMed ID: 33730386
[TBL] [Abstract][Full Text] [Related]
18. Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma.
Chao WR; Lee MY; Lee YJ; Sheu GT; Han CP
Virchows Arch; 2022 May; 480(5):1023-1030. PubMed ID: 35226147
[TBL] [Abstract][Full Text] [Related]
19. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
20. Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Hagemann IS; Bridge JA; Tafe LJ; Hameed MR; Moncur JT; Bellizzi AM; Dolan M; Vasalos P; Kane ME; Souers RJ; Yemelyanova A
Arch Pathol Lab Med; 2023 Oct; 147(10):1148-1157. PubMed ID: 36538387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
